SRPT Quantitative Stock Analysis | Nasdaq
Below is Validea’s guru fundamental report for SAREPTA THERAPEUTICS INC (SRPT). Of the 22 guru strategies we follow, SRPT rates highest using our Contrarian Investor model based on the published strategy of David Dreman. This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.
SAREPTA THERAPEUTICS INC (SRPT) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 64% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or…
